Cargando…

ctDNA Is Useful to Detect Mutations at Codon 641 of Exon 16 of EZH2, a Biomarker for Relapse in Patients with Diffuse Large B-Cell Lymphoma

SIMPLE SUMMARY: It is well known that epigenetic modifications and proteins involved in this process are important in the biogenesis of diffuse large B-cell lymphoma. In this sense, we decided to analyze the EZH2 mutations, which are frequent in this neoplasm, using ctDNA to demonstrate the utility...

Descripción completa

Detalles Bibliográficos
Autores principales: Díaz-Chávez, José, Gutiérrez-Hernández, Olga, Taja-Chayeb, Lucia, Gutiérrez-Chavarría, Sindy, Avilés-Salas, Alejandro, Candelaria, Myrna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9563768/
https://www.ncbi.nlm.nih.gov/pubmed/36230571
http://dx.doi.org/10.3390/cancers14194650
_version_ 1784808482604580864
author Díaz-Chávez, José
Gutiérrez-Hernández, Olga
Taja-Chayeb, Lucia
Gutiérrez-Chavarría, Sindy
Avilés-Salas, Alejandro
Candelaria, Myrna
author_facet Díaz-Chávez, José
Gutiérrez-Hernández, Olga
Taja-Chayeb, Lucia
Gutiérrez-Chavarría, Sindy
Avilés-Salas, Alejandro
Candelaria, Myrna
author_sort Díaz-Chávez, José
collection PubMed
description SIMPLE SUMMARY: It is well known that epigenetic modifications and proteins involved in this process are important in the biogenesis of diffuse large B-cell lymphoma. In this sense, we decided to analyze the EZH2 mutations, which are frequent in this neoplasm, using ctDNA to demonstrate the utility of this tool for searching these mutations. The importance of the study of this gene is due to its role in the biogenesis of lymphomas and also because there are selective inhibitors targeting EZH2. This targeted therapy could be particularly effective in patients with activating mutations in EZH2, remarking the importance of its detection. ABSTRACT: (1) Background: The epigenetic regulator EZH2 is a subunit of the polycomb repressive complex 2 (PRC2), and methylates H3K27, resulting in transcriptional silencing. It has a critical role in lymphocyte differentiation within the lymph node. Therefore, mutations at this level are implicated in lymphomagenesis. In fact, the mutation at the Y641 amino acid in the EZH2 gene is mutated in up to 40% of B-cell lymphomas. (2) Methods: We compared the presence of exon 16 EZH2 mutations in tumor samples and ctDNA in a prospective trial. These mutations were determined by Sanger sequencing and ddPCR. (3) Results: One hundred and thirty-eight cases were included. Ninety-eight were germinal center, and twenty had EZH2 mutations. Mean follow-up (IQR 25–75) was 23 (7–42) months. The tumor samples were considered the standard of reference. Considering the results of the mutation in ctDNA by Sanger sequencing, the sensibility (Se) and specificity (Sp) were 52% and 99%, respectively. After adding the droplet digital PCR (ddPCR) analysis, the Se and Sp increased to 95% and 100%, respectively. After bivariate analysis, only the presence of double-hit lymphoma (p = 0.04) or EZH2 mutations were associated with relapse. The median Progression free survival (PFS) (95% interval confidence) was 27.7 (95% IC: 14–40) vs. 44.1 (95% IC: 40–47.6) months for the mutated vs. wild-type (wt) patients. (4) Conclusions: The ctDNA is useful for analyzing EZH2 mutations, which have an impact on PFS.
format Online
Article
Text
id pubmed-9563768
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-95637682022-10-15 ctDNA Is Useful to Detect Mutations at Codon 641 of Exon 16 of EZH2, a Biomarker for Relapse in Patients with Diffuse Large B-Cell Lymphoma Díaz-Chávez, José Gutiérrez-Hernández, Olga Taja-Chayeb, Lucia Gutiérrez-Chavarría, Sindy Avilés-Salas, Alejandro Candelaria, Myrna Cancers (Basel) Article SIMPLE SUMMARY: It is well known that epigenetic modifications and proteins involved in this process are important in the biogenesis of diffuse large B-cell lymphoma. In this sense, we decided to analyze the EZH2 mutations, which are frequent in this neoplasm, using ctDNA to demonstrate the utility of this tool for searching these mutations. The importance of the study of this gene is due to its role in the biogenesis of lymphomas and also because there are selective inhibitors targeting EZH2. This targeted therapy could be particularly effective in patients with activating mutations in EZH2, remarking the importance of its detection. ABSTRACT: (1) Background: The epigenetic regulator EZH2 is a subunit of the polycomb repressive complex 2 (PRC2), and methylates H3K27, resulting in transcriptional silencing. It has a critical role in lymphocyte differentiation within the lymph node. Therefore, mutations at this level are implicated in lymphomagenesis. In fact, the mutation at the Y641 amino acid in the EZH2 gene is mutated in up to 40% of B-cell lymphomas. (2) Methods: We compared the presence of exon 16 EZH2 mutations in tumor samples and ctDNA in a prospective trial. These mutations were determined by Sanger sequencing and ddPCR. (3) Results: One hundred and thirty-eight cases were included. Ninety-eight were germinal center, and twenty had EZH2 mutations. Mean follow-up (IQR 25–75) was 23 (7–42) months. The tumor samples were considered the standard of reference. Considering the results of the mutation in ctDNA by Sanger sequencing, the sensibility (Se) and specificity (Sp) were 52% and 99%, respectively. After adding the droplet digital PCR (ddPCR) analysis, the Se and Sp increased to 95% and 100%, respectively. After bivariate analysis, only the presence of double-hit lymphoma (p = 0.04) or EZH2 mutations were associated with relapse. The median Progression free survival (PFS) (95% interval confidence) was 27.7 (95% IC: 14–40) vs. 44.1 (95% IC: 40–47.6) months for the mutated vs. wild-type (wt) patients. (4) Conclusions: The ctDNA is useful for analyzing EZH2 mutations, which have an impact on PFS. MDPI 2022-09-24 /pmc/articles/PMC9563768/ /pubmed/36230571 http://dx.doi.org/10.3390/cancers14194650 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Díaz-Chávez, José
Gutiérrez-Hernández, Olga
Taja-Chayeb, Lucia
Gutiérrez-Chavarría, Sindy
Avilés-Salas, Alejandro
Candelaria, Myrna
ctDNA Is Useful to Detect Mutations at Codon 641 of Exon 16 of EZH2, a Biomarker for Relapse in Patients with Diffuse Large B-Cell Lymphoma
title ctDNA Is Useful to Detect Mutations at Codon 641 of Exon 16 of EZH2, a Biomarker for Relapse in Patients with Diffuse Large B-Cell Lymphoma
title_full ctDNA Is Useful to Detect Mutations at Codon 641 of Exon 16 of EZH2, a Biomarker for Relapse in Patients with Diffuse Large B-Cell Lymphoma
title_fullStr ctDNA Is Useful to Detect Mutations at Codon 641 of Exon 16 of EZH2, a Biomarker for Relapse in Patients with Diffuse Large B-Cell Lymphoma
title_full_unstemmed ctDNA Is Useful to Detect Mutations at Codon 641 of Exon 16 of EZH2, a Biomarker for Relapse in Patients with Diffuse Large B-Cell Lymphoma
title_short ctDNA Is Useful to Detect Mutations at Codon 641 of Exon 16 of EZH2, a Biomarker for Relapse in Patients with Diffuse Large B-Cell Lymphoma
title_sort ctdna is useful to detect mutations at codon 641 of exon 16 of ezh2, a biomarker for relapse in patients with diffuse large b-cell lymphoma
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9563768/
https://www.ncbi.nlm.nih.gov/pubmed/36230571
http://dx.doi.org/10.3390/cancers14194650
work_keys_str_mv AT diazchavezjose ctdnaisusefultodetectmutationsatcodon641ofexon16ofezh2abiomarkerforrelapseinpatientswithdiffuselargebcelllymphoma
AT gutierrezhernandezolga ctdnaisusefultodetectmutationsatcodon641ofexon16ofezh2abiomarkerforrelapseinpatientswithdiffuselargebcelllymphoma
AT tajachayeblucia ctdnaisusefultodetectmutationsatcodon641ofexon16ofezh2abiomarkerforrelapseinpatientswithdiffuselargebcelllymphoma
AT gutierrezchavarriasindy ctdnaisusefultodetectmutationsatcodon641ofexon16ofezh2abiomarkerforrelapseinpatientswithdiffuselargebcelllymphoma
AT avilessalasalejandro ctdnaisusefultodetectmutationsatcodon641ofexon16ofezh2abiomarkerforrelapseinpatientswithdiffuselargebcelllymphoma
AT candelariamyrna ctdnaisusefultodetectmutationsatcodon641ofexon16ofezh2abiomarkerforrelapseinpatientswithdiffuselargebcelllymphoma